<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813760</url>
  </required_header>
  <id_info>
    <org_study_id>CYN12-AFF-UL-09</org_study_id>
    <nct_id>NCT01813760</nct_id>
  </id_info>
  <brief_title>Treatment of Periorbital and Perioral Wrinkles With the Applications of the Iluminage Diode Laser</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Diode laser system is being used in this marketing study for the treatment of wrinkles&#xD;
      around the eyes and mouth.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photographic Evaluation</measure>
    <time_frame>60 days post first treatment</time_frame>
    <description>Compare severity of wrinkles from baseline to 60 days post treatment based on Fitpatrick Scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>up to 4 months post 1st treatment</time_frame>
    <description>Adverse events and side effects will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photographic Evaluation</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>Compare severity of wrinkles from baseline to 1,10, 20 and 40 days post treatment based on Fitzpatrick Scale.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Peri-orbital Wrinkles</condition>
  <condition>Peri-oral Wrinkles</condition>
  <arm_group>
    <arm_group_label>Diode laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diode laser to treat peri-orbital and peri-oral wrinkles</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Illuiminage ® Diode Laser</intervention_name>
    <description>Diode laser for treatment of peri-orbital and peri-oral wrinkles</description>
    <arm_group_label>Diode laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are healthy females between 35 and 60 years of age.&#xD;
&#xD;
          2. Subjects who have Fitzpatrick skin type I-VI&#xD;
&#xD;
          3. Subjects who have provided written and verbal informed consent&#xD;
&#xD;
          4. Subjects who are willing and able to comply with study instructions and to return to&#xD;
             the clinic for required visits and have photographs of their face taken&#xD;
&#xD;
          5. Subjects who have perioral and periorbital wrinkles, as deemed appropriate by the&#xD;
             Investigator or his designees&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who currently use or have used in the prior 30 days any skin products that&#xD;
             contain alpha hydroxy acids (AHA) e.g. glycolic, lactic, citric, or mendelic acid&#xD;
             containing products or retinol/tretinoin containing products or exfoliating washes,&#xD;
             masks or scrubs or other micro-dermabrasion skin care products. on the laser&#xD;
             application areas&#xD;
&#xD;
          2. Subjects who are unwilling to maintain their daily skin care regimen for the duration&#xD;
             of the study,&#xD;
&#xD;
          3. Subjects who have any skin pathology or condition that could interfere with the&#xD;
             evaluation i.e. personal or family history of skin cancer, rosacea and/or requires the&#xD;
             use of interfering topical or systemic therapies.&#xD;
&#xD;
          4. Subjects with synthetic or metal implants or permanent cosmetic tattoos in the test&#xD;
             areas&#xD;
&#xD;
          5. Subjects who have a history of abnormal scarring, e.g. keloids or have significant&#xD;
             scarring in the areas to be treated&#xD;
&#xD;
          6. Subjects with bleeding disorders or taking anticoagulation medications, including&#xD;
             heavy use of aspirin&#xD;
&#xD;
          7. Subjects who have participated in any clinical investigation involving the face within&#xD;
             the 30 days prior to the first planned laser application or subjects who plan to&#xD;
             participate in concomitant facial studies during this trial&#xD;
&#xD;
          8. Subjects, who are pregnant, were pregnant or gave birth in the last 3 months, are&#xD;
             currently breast feeding, or might become pregnant during the course of the study&#xD;
&#xD;
          9. Subjects who have a history of light triggered seizures&#xD;
&#xD;
         10. Subjects with prior use of neurotoxins e.g. Botox®, collagen, fat injections and/or&#xD;
             other methods of skin augmentation (enhancement with injected or implanted material)&#xD;
             of the face or having had chemical peels within 6 months of initial laser application&#xD;
             or planning to so during the course of the study&#xD;
&#xD;
         11. Subject's use of oral isotretinoin (Accutane®) within 12 months of initial laser&#xD;
             application or during the course of the study&#xD;
&#xD;
         12. Subjects having had facial skin treatments with any professional laser, light based,&#xD;
             radiofrequency or other devices within the last year&#xD;
&#xD;
         13. Subjects ever having facial skin treatments with home use laser, light based or&#xD;
             radiofrequency or other devices, i.e. PaloVia® or Tria®&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cynosure, Inc</name>
      <address>
        <city>Westford</city>
        <state>Massachusetts</state>
        <zip>01886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

